Jiangsu Cancer Institute & Hospital

This study tests whether giving a combination of two drugs (becotatug vedotin and putlimab) before surgery, followed by radiotherapy and more putlimab after surgery, can improve outcomes for people with locally advanced head and neck cancer. The trial enrolls about 35 participant…

This phase 2 trial is testing a combination of two targeted drugs (fruquintinib and serplulimab) plus chemotherapy as a first treatment for 80 people with advanced colorectal cancer that has RAS or BRAF mutations. The goal is to see if this mix can delay cancer growth and improve…

This study tests a new combination of drugs for people with advanced colorectal cancer that cannot be removed by surgery. About 70 participants will receive two immunotherapy drugs plus a targeted therapy and chemotherapy. The goal is to see if this combination can shrink tumors …

This phase II trial tests whether adding low-dose radiotherapy and the immunotherapy drug tislelizumab to standard chemotherapy can improve outcomes for people with locally advanced stomach or gastroesophageal junction cancer. About 114 participants will be randomly assigned to r…

This Phase 2 trial will test a combination of the experimental drug QL1706 with standard chemotherapy or with olaparib and intraperitoneal chemotherapy as a pre-surgery treatment for 50 women with advanced ovarian cancer. The goal is to see if this approach can shrink tumors enou…

This trial tests a new approach for people with early-stage non-small cell lung cancer that can be removed with surgery. Before surgery, patients receive a combination of targeted radiation (SBRT), two immunotherapy drugs (iparomlimab and tuvonralimab, also called QL1706), and ch…

This study looks for biological markers in people with nasopharyngeal carcinoma to help predict how the disease will progress and how well treatments might work. Researchers will analyze tissue samples from 60 newly diagnosed patients who have not had their cancer spread. The goa…